Competitor ad tracking for multi-specialty hospitals in India (2026): 12-25 sub-specialty channels, brand vs service ad split, cross-specialty reallocation, and PrismSpy's portfolio lens

Competitor ad tracking for multi-specialty hospitals in India is a different discipline from tracking a single-specialty clinic. A tertiary hospital brand does not run "hospital Meta ads" — it runs 12-25 sub-specialty campaigns in parallel from the same brand handle, each with its own CPL band, its own competitor set, its own creative refresh cadence, and its own compliance surface. Cardiac ads in the tracked hospital cluster run at a CPL around ₹3,200. Orthopaedics runs at ₹1,400. Oncology, gynaecology, gastroenterology, urology, paediatrics, nephrology, neurology and pulmonology sit in between, each with its own economics. The interesting question for a hospital marketing head is rarely which sub-specialty ads are running — it is where competitor spend is shifting between sub-specialties, and whether the hospital's own portfolio is allocated to match the demand. This piece walks through what PrismSpy's multi-specialty hospital view actually watches daily, why brand-versus-service ad splits matter, how NMC, DPDP, JCI/NABH and ABDM shape the copy, and where cross-specialty reallocation earns its keep.

A hospital doesn't run "hospital Meta ads" — it runs 12-25 parallel specialty channels

Meta Catalyst IQ long-term comparison view charting Meta Ads performance across quarters with spend, CPQL and volume overlaid" width="1200" height="675" loading="lazy" decoding="async" style="width:100%;height:auto;display:block;">

Inside a tertiary multi-specialty hospital's Meta ad account, the specialties in flight on any given day typically include cardiology (with a sub-split of interventional, electrophysiology, cardiac surgery), oncology (medical, surgical, radiation, sometimes haem-onc separately), orthopaedics (joint replacement, spine, sports injury), gynaecology and obstetrics, IVF where the hospital has an ART clinic, paediatrics, neurology and neurosurgery, gastroenterology and hepatology, urology and nephrology, pulmonology, ENT, ophthalmology, dermatology at the OP end, and endocrinology. Preventive health check packages sit alongside as their own campaign line.

Each sub-specialty is competing against a different competitor set on Meta. Cardiac ads compete against other tertiary hospitals' cardiac campaigns plus dedicated heart-hospital chains. Oncology ads compete against dedicated cancer centres plus other tertiary oncology programmes. Ortho ads compete against joint-replacement specialty clinics as well as other hospitals. The competitor set for one hospital's Meta account is not one list — it is 12-25 overlapping lists, and the reading of each list is different.

PrismSpy's hospital view is set up as a portfolio scan across all the sub-specialties the hospital runs, with per-specialty watchlists cross-referenced against the hospital's own campaign structure. The output is not a single competitor briefing but a portfolio of them.

The brand-vs-service ad split every hospital marketing head negotiates

Every hospital marketing head negotiates the same internal argument: how much of the monthly Meta ad budget goes to brand-first creative (the hospital as an institution — trust, credentials, JCI/NABH accreditation, senior clinician panels, technology infrastructure) and how much goes to service-first creative (specific procedure ads with specific offers, EMI framings, package prices, consultation windows).

Brand-first ads build awareness and long-tail preference. They typically show a lower short-run CPL when measured as cost-per-branded-search-lift or cost-per-website-visit, and a higher CPL when measured as cost-per-appointment-booked. Service-first ads convert directly and are measured on cost-per-appointment or cost-per-qualified-lead, which for most sub-specialties will look tighter in a monthly dashboard.

The tracked hospital cluster shows a clean split by hospital type:

• National multi-city hospital chains run 25-35 per cent brand-first, 65-75 per cent service-first, with brand-first heavy in cities where the chain is newer.
• Standalone flagship tertiary hospitals run 15-25 per cent brand-first, 75-85 per cent service-first, because their brand is already known in the primary catchment.
• Regional multi-specialty hospitals with 2-4 units run 10-20 per cent brand-first, because service-line volume is what the P&L needs weekly.

Reading the competitor cluster through PrismSpy shows where each competitor is currently allocating between brand and service creative, which is a leading indicator of that competitor's medium-term strategy — a competitor lifting brand-first share in a new city is usually preparing to expand there; a competitor cutting brand-first share is usually protecting near-term P&L.

Cardiac Meta ads — CPL ₹3,200 and the discipline that reduces it

Cardiac is the highest-CPL specialty on the multi-specialty Meta ad map. The tracked cluster shows a CPL benchmark around ₹3,200 for cardiac campaigns — well above ortho (₹1,400) and multiples of primary-care dental or dermatology. Three things drive the cardiac CPL up: the audience is narrow and older-skewing (targeting economics are harder), the funnel is longer (a cardiac enquiry often takes 30-60 days from first ad to admission), and the ad copy is compliance-heavy because the NMC Ethics Code 2026 constrains outcome and superiority framing tightly.

Where cardiac CPL comes down in the disciplined operators is on three levers: a symptom-specific hook (chest pain that comes with exertion, palpitations on exercise, sudden breathlessness at rest) rather than a specialty-umbrella hook; a senior interventional or CT-surgery specialist on camera as the E-E-A-T signal; and a landing page that anchors on a specific diagnostic pathway (ECG, echo, TMT, angiography) with transparent pricing rather than a generic cardiology consultation booking.

Orthopaedics — CPL ₹1,400 and where reallocation shows up

Ortho sits in the middle of the multi-specialty CPL map at ₹1,400, with joint replacement running slightly higher than sports injury or general ortho. It is often the specialty where hospital marketing heads discover the reallocation problem first — because when cardiac CPL rises 15 per cent quarter-on-quarter (competitor spend spike, seasonal audience shift, creative fatigue), the natural move is to reallocate to ortho where CPL is lower and the P&L contribution per case is still meaningful. PrismSpy's cross-specialty view is what surfaces the timing signal: which specialty is currently absorbing marginal budget best, based on competitor pressure and cluster CPL drift.

Oncology, gynaecology, gastro — the middle-band specialties on Meta

The middle-band specialties (oncology, gynaecology and obstetrics, gastroenterology and hepatology, urology, neurology and neurosurgery, pulmonology, nephrology) run CPLs between ₹1,400 and ₹3,000 with wide variance driven by procedure specificity and city-level competitor density. Two structural notes across the tracked cluster:

Oncology ads are compliance-first, like IVF. The NMC Ethics Code 2026 constrains superiority claims heavily in oncology, and outcome framing has to be careful. Mature oncology creative anchors on multi-disciplinary tumour boards, technology (linear accelerator, robotic surgery, precision oncology diagnostics), and second-opinion offers rather than survival claims.

Gynaecology and obstetrics is a two-audience specialty. The obstetric side (antenatal, delivery packages, NICU capability) targets a younger audience with a much shorter decision window; the gynae side (fibroids, endometriosis, laparoscopic surgery, oncology overlap) targets a broader age band with a longer decision window. Running them under one gynae campaign structure is a common misconfiguration that inflates CPL on both sides.

Gastroenterology and hepatology is the fastest-growing sub-specialty in the tracked hospital cluster in 2026, driven by rising demand for endoscopy, colonoscopy, liver disease evaluation and bariatric consultations. Ad spend share is moving toward gastro across the cluster, which shows up in PrismSpy's activity feed as a share-of-voice shift.

Cross-specialty spend reallocation — where PrismSpy actually earns its keep

The single most valuable use of PrismSpy for a multi-specialty hospital is not per-specialty creative intelligence — it is the cross-specialty portfolio view that surfaces where marginal ad budget should move next. Reading the tracked cluster through this lens each week produces answers to questions like:

• Is cardiac CPL rising this month because our creative is fatigued, or because two competitor hospitals in the city are running an active cardiac spend push?
• Is orthopaedics under-invested this quarter relative to what competitor ortho spend is doing?
• Is gastro spend at cluster level moving faster than our own gastro allocation is scaling?
• Is our brand-first share below the cluster average for a city where a competitor is doing an expansion?

These decisions used to be made in a monthly review meeting on opinion and gut. With PrismSpy running underneath — and Meta Catalyst IQ pulling that intelligence into weekly reallocation decisions on the actual ad account — they are made on daily data. ICG's multi-specialty hospital engagements route through this loop.

Multi-city GMB competitor overlay

Multi-specialty hospitals with a multi-city footprint (2, 5, 15 units across cities) have another layer PrismSpy runs alongside: the per-city GMB competitive standing for each unit. A Meta ad running for a specific unit in a specific city converts at a rate that depends heavily on that unit's GMB profile in that city — the review volume, the average rating, the answered-question density, the photo count, the response speed to reviews. Two units of the same hospital chain can run identical ads with 40 per cent CPL differential purely because of GMB standing gaps.

PrismSpy's hospital view reads the Meta ad cluster and the local GMB competitor set together, so the ad plan for each unit is calibrated to that unit's local competitive reality rather than to a national chain average.

NMC, DPDP, JCI/NABH accreditation, and hospital ad copy

Hospital advertising in India sits inside a denser compliance frame than most single-specialty clinic advertising: the NMC Ethics Code 2026 (superiority and outcome claims), the DPDP Act 2023 (patient data handling in any ad-response workflow, especially WhatsApp and lead-form pixels), the ASCI Guidelines 2022 (substantiation of any before-after or comparative claim), JCI or NABH accreditation representation (correctly stating current accreditation status, avoiding out-of-date claims), and the Clinical Establishments (Registration and Regulation) Act where applicable.

The mature hospital brands in the tracked cluster tend to represent accreditation prominently (NABH, JCI, subject-area programme accreditations) as a trust signal in brand-first creative, keep outcome and superiority claims out of service-first creative, and route any lead-capture flow through a DPDP-conscious consent architecture. Less-disciplined operators mix all three and carry compliance exposure across the ad set.

ABDM and the digital-first hospital ad narrative

The Ayushman Bharat Digital Mission (ABDM) is quietly reshaping how hospitals talk about themselves in ads. ABHA-enabled digital patient records, tele-consultation-first pathways, and integrated referral networks are becoming ad-worthy trust signals for hospital brands that have invested in the digital-first infrastructure. The tracked cluster shows a slow but consistent rise in ad copy that references ABDM readiness, ABHA integration, and continuous digital care journeys — a signal that the digital-first narrative is starting to work as differentiation.

Powered by PrismSpy — every competitor Meta ad, watched daily

ICG built PrismSpy because Indian healthcare Meta ad competition is invisible without it — and multi-specialty hospital advertising is the case where invisibility is most expensive, because 12-25 sub-specialty channels running in parallel produces 12-25 blind spots at once without a portfolio scan underneath. 75+ Indian healthcare brands tracked, 2,150+ active ads catalogued, ₹50Cr+ aggregate ad spend visibility per month. Every competitor ad — creative, offer, hook, run-length — refreshed daily. It runs underneath every Meta ads and performance marketing engagement at ICG.

• Watchlist Dashboard — 30-75 competitors per specialty cluster (IVF / dermatology / dental / hair transplant / aesthetic / hospital), daily refresh.
• Comparative Insights — highest-quality ads, longest-running creatives (proven converters), top hooks, emerging offers.
• Offers Intelligence — 1,197 offers tracked, discount intensity by brand, value tier distribution.
• Service Cluster + Inspirations — 419 services tracked, 4,697 searchable ad inspirations by hook / language / format.

Standalone from ₹4,999/- per specialty vertical, or bundled free inside HealthApex OS (₹14,999/- flat, 9 tools). Book a 30-min PrismSpy walkthrough on WhatsApp — Rohit + Hanuman walk you through your specialty's competitive landscape.

angryturtle/01-listing-overview.png" alt="Angryturtle Listing Overview — GBP watchlist with per-listing status, category, sub-scores, action count for 143+ managed Indian healthcare listings" loading="lazy" decoding="async" style="width:100%;height:auto;display:block;">

FAQ

Q. How many sub-specialty campaigns does a typical multi-specialty hospital run on Meta?
A. Twelve to twenty-five, depending on the hospital's service line depth. Cardiac, oncology, orthopaedics, gynaecology and obstetrics, gastroenterology, urology, neurology, paediatrics, pulmonology, nephrology, ENT and ophthalmology are common. Preventive health check packages usually run as their own campaign line.

Q. What is the CPL benchmark for cardiac Meta ads in India?
A. The tracked hospital cluster shows a cardiac CPL benchmark around ₹3,200 — the highest among the common multi-specialty sub-specialties. Orthopaedic CPL sits around ₹1,400. Middle-band specialties (oncology, gastro, gynae) run in the ₹1,400-₹3,000 range with wide variance driven by procedure specificity and city-level competitor density.

Q. How should a hospital split budget between brand-first and service-first ads?
A. There is no universal split, but the tracked cluster shows national chains at 25-35 per cent brand-first, standalone flagships at 15-25 per cent, and regional 2-4 unit groups at 10-20 per cent. Brand-first share rises in newer-catchment cities and falls where the brand is already established.

Q. Where does PrismSpy help most on a multi-specialty hospital engagement?
A. The cross-specialty portfolio view — surfacing which sub-specialties competitor spend is moving toward, where the hospital's own allocation is under- or over-weighted, and which sub-specialty CPLs are rising due to competitor pressure rather than internal creative fatigue. That intelligence drives weekly reallocation decisions rather than monthly ones.

Q. How does JCI or NABH accreditation show up in Meta ad copy?
A. In the mature hospital cluster, accreditation appears prominently in brand-first creative as a trust signal and is represented accurately (current accreditation status, no out-of-date claims). It is usually absent from service-first creative where the offer or procedure specificity carries the ad instead.

Q. Do multi-city hospital chains need per-city ad strategies?
A. Yes. Each unit's GMB standing in its city changes the on-clinic conversion rate of an identical Meta ad. PrismSpy's hospital view reads the Meta ad cluster and the local GMB competitor set together, so the ad plan for each unit is calibrated to local competitive reality rather than a national chain average.

Q. Is ABDM integration something patients actually respond to in ads?
A. Slowly, yes. The tracked cluster shows a rising share of ad copy referencing ABHA integration, tele-consultation-first pathways, and continuous digital care journeys — as ABDM adoption widens, digital-first infrastructure is becoming a legible differentiator, especially for younger patient audiences.

Related reading

• Hospital marketing agency in India — pillar guide
• Healthcare Meta Ads agency in India
• Healthcare performance marketing service page
• Healthcare Meta Ads service page
• HealthApex OS — 9-tool healthcare growth stack
• Book a free hospital competitive audit

Authority references: National Medical Commission · Ayushman Bharat Digital Mission · Ministry of Health and Family Welfare